02/14/2019
For many asthma and chronic obstructive pulmonary disease (COPD) patients across the country, this means significantly more affordable drugs.
The U.S. Food and Drug Administration released the news in late January that the first generic version of ADVAIR DISKUS has been approved. As a result, Mylan Pharmaceuticals has been allowed to market three strengths of this inhaler. For many asthma and chronic obstructive pulmonary disease (COPD) p...